StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.90−0.03 (-1.55%)

Close on Nov 17, 2026Market cap $18.96MP/E –Yield –

Atossa Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Atossa Therapeutics's total assets was $32.28M at Jun 30, 2026. For fiscal 2025 it was $47.61M, down 37.7% from the year before. Over ten years it grew 22.5% a year on average. The highest annual figure on record is $141.26M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$47.61M-37.7%
FY2024Dec 31, 2024$76.44M-20.6%
FY2023Dec 31, 2023$96.25M-22.1%
FY2022Dec 31, 2022$123.53M-12.6%
FY2021Dec 31, 2021$141.26M+229.8%
FY2020Dec 31, 2020$42.84M+195.6%
FY2019Dec 31, 2019$14.49M+23.6%
FY2018Dec 31, 2018$11.72M+43.6%
FY2017Dec 31, 2017$8.16M+97.0%
FY2016Dec 31, 2016$4.14M-33.6%
FY2015Dec 31, 2015$6.24M-46.9%
FY2014Dec 31, 2014$11.76M-2.0%
FY2013Dec 31, 2013$12.01M+75.9%
FY2012Dec 31, 2012$6.83M+122.2%
FY2011Dec 31, 2011$3.07M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$32.28M-50.0%
Q1 FY2026Mar 31, 2026$37.94M-46.4%
Q4 FY2025Dec 31, 2025$47.61M-37.7%
Q3 FY2025Sep 30, 2025$58.01M-27.0%
Q2 FY2025Jun 30, 2025$64.52M-24.9%
Q1 FY2025Mar 31, 2025$70.75M-22.3%
Q4 FY2024Dec 31, 2024$76.44M-20.6%
Q3 FY2024Sep 30, 2024$79.48M-21.8%
Q2 FY2024Jun 30, 2024$85.86M-20.8%
Q1 FY2024Mar 31, 2024$91.09M-21.6%
Q4 FY2023Dec 31, 2023$96.25M-22.1%
Q3 FY2023Sep 30, 2023$101.70M-19.8%
Q2 FY2023Jun 30, 2023$108.36M-19.2%
Q1 FY2023Mar 31, 2023$116.20M-15.5%
Q4 FY2022Dec 31, 2022$123.53M-12.6%
Q3 FY2022Sep 30, 2022$126.72M-11.4%
Q2 FY2022Jun 30, 2022$134.05M-8.1%
Q1 FY2022Mar 31, 2022$137.48M-2.6%
Q4 FY2021Dec 31, 2021$141.26M+229.8%
Q3 FY2021Sep 30, 2021$143.02M+1150.5%
Q2 FY2021Jun 30, 2021$145.87M+1329.3%
Q1 FY2021Mar 31, 2021$141.08M+1094.4%
Q4 FY2020Dec 31, 2020$42.84M+195.6%
Q3 FY2020Sep 30, 2020$11.44M-31.1%
Q2 FY2020Jun 30, 2020$10.21M-45.2%
Q1 FY2020Mar 31, 2020$11.81M-43.8%
Q4 FY2019Dec 31, 2019$14.49M+23.6%
Q3 FY2019Sep 30, 2019$16.60M+17.5%
Q2 FY2019Jun 30, 2019$18.61M+12.3%
Q1 FY2019Mar 31, 2019$21.02M+251.6%
Q4 FY2018Dec 31, 2018$11.72M+43.6%
Q3 FY2018Sep 30, 2018$14.12M+288.6%
Q2 FY2018Jun 30, 2018$16.58M+252.0%
Q1 FY2018Mar 31, 2018$5.98M+159.7%
Q4 FY2017Dec 31, 2017$8.16M+97.0%
Q3 FY2017Sep 30, 2017$3.63M-42.1%
Q2 FY2017Jun 30, 2017$4.71M–
Q1 FY2017Mar 31, 2017$2.30M–
Q4 FY2016Dec 31, 2016$4.14M–
Q3 FY2016Sep 30, 2016$6.28M–

More Atossa Therapeutics figures

See a number that looks wrong?